Falakef suukaudse suspensiooni pulber Eesti - eesti - Ravimiamet

falakef suukaudse suspensiooni pulber

nextmune italy s.r.l. - tsefaleksiin - suukaudse suspensiooni pulber - 50mg 1ml 100ml 1tk; 50mg 1ml 60ml 1tk

IMIPENEM/CILASTATIN KABI infusioonilahuse pulber Eesti - eesti - Ravimiamet

imipenem/cilastatin kabi infusioonilahuse pulber

fresenius kabi polska sp. z o.o. - imipeneem+tsilastatiin - infusioonilahuse pulber - 500mg+500mg 20ml 10tk; 500mg+500mg 100ml 10tk

IMIPENEM/CILASTATIN KABI infusioonilahuse pulber Eesti - eesti - Ravimiamet

imipenem/cilastatin kabi infusioonilahuse pulber

fresenius kabi polska sp. z o.o. - imipeneem+tsilastatiin - infusioonilahuse pulber - 250mg+250mg 20ml 10tk

Palforzia Euroopa Liit - eesti - EMA (European Medicines Agency)

palforzia

aimmune therapeutics ireland limited - defatted powder of arachis hypogaea l., semen (peanuts) - peanut hypersensitivity - allergens - palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. palforzia may be continued in patients 18 years of age and older. palforzia should be used in conjunction with a peanut-avoidant diet.

Imcivree Euroopa Liit - eesti - EMA (European Medicines Agency)

imcivree

rhythm pharmaceuticals netherlands b.v. - setmelanotide - rasvumine - antiobesioonipreparaadid, va dieedi tooted - imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed bardet biedl syndrome (bbs), loss-of-function biallelic pro-opiomelanocortin (pomc), including pcsk1, deficiency or biallelic leptin receptor (lepr) deficiency in adults and children 6 years of age and above.

Voxzogo Euroopa Liit - eesti - EMA (European Medicines Agency)

voxzogo

biomarin international limited - vosoritide - achondroplasia - narkootikumid luuhaiguste raviks - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

Ontilyv Euroopa Liit - eesti - EMA (European Medicines Agency)

ontilyv

bial portela & companhia s.a. - opikapoon - parkinsoni tõbi - parkinsoni tõve ravimid - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

BENDAMUSTINE ACCORD infusioonilahuse kontsentraat Eesti - eesti - Ravimiamet

bendamustine accord infusioonilahuse kontsentraat

accord healthcare b.v. - bendamustiin - infusioonilahuse kontsentraat - 25mg 1ml 1ml 5tk; 25mg 1ml 4ml 5tk

Zokinvy Euroopa Liit - eesti - EMA (European Medicines Agency)

zokinvy

eigerbio europe limited - lonafarnib - progeria; laminopathies - muud alimentary seedetrakti ja ainevahetust tooted, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.

Upstaza Euroopa Liit - eesti - EMA (European Medicines Agency)

upstaza

ptc therapeutics international limited - eladocagene exuparvovec - aminohapete ainevahetus, kaasasündinud vead - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.